Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia by Lepper, Philipp M. et al.
LETTER
Blood glucose, diabetes and metabolic control in patients
with community-acquired pneumonia
Philipp M. Lepper1 & Robert Bals1 & Peter Jüni2,3 & Maximilian von Eynatten4
Received: 18 June 2020 /Accepted: 25 June 2020
# The Author(s) 2020




SARS-CoV2 Coronavirus severe acute
respiratory syndrome coronavirus 2
To the Editor:We read with interest the studies by Cariou et al
[1] andWang et al [2] published in the journal. Evidence so far
suggests that type 2 diabetes mellitus may not increase the
overall risk of an infection with the novel coronavirus severe
acute respiratory syndrome coronavirus 2 (SARS-CoV2) [3],
the causal agent of a syndrome called coronavirus disease-
2019 (COVID-19); however, pre-existing type 2 diabetes
appears to be associated with more severe infection [4].
Moreover, recent evidence by Zhu et al [5] and data from an
observational NHS England cohort [6, 7], consistently
showed an increased risk for COVID-19-related death in
patients with type 2 diabetes. The study by Cariou et al [1]
adds to current knowledge by reporting that higher BMI (but
not long-term glycaemic control or type of glucose-lowering
therapy used) was significantly associated with the severity of
COVID-19 infection as studied in their cohort of 1317 patients
with pre-existing diabetes (89% with type 2 diabetes). Wang
and colleagues analysed whether blood glucose taken within
24 h of admission after a fasting period was a predictive mark-
er for 28-day mortality in 605 COVID-19 patients without
diabetes [2]. They found that patients with fasting serum
glucose concentrations ≥7.0 mmol/l had a significantly higher
risk of death (HR 2.30; 95% CI 1.49, 3.55; p = 0.0002).
Hence, currently available evidence on clinical risk manage-
ment in patients with COVID-19 strongly supports the inclu-
sion of assessment of diabetes status as well as careful consid-
eration of additional clinical attributes, such as BMI and blood
glucose levels.
These important insights may have just recently emerged
for COVID-19; however, previous evidence in clinical
community-acquired pneumonia (CAP) research has already
identified the importance of pre-existing diabetes for outcome
risk assessment. We conducted a large prospective study in
6891 Caucasian patients admitted for CAP due to causes other
than SARS-CoV2 to 12 German centres [8]. We explored
whether pre-existing diabetes would be associated with an
increased mortality risk from CAP caused by any infectious
agent [8]. The 28-day mortality risk was significantly
increased in the 1114 participants with diabetes compared
with that in individuals without diabetes with normal serum
glucose levels (adjusted HR 1.92; 95% CI 1.34, 2.75;
p < 0.001).
Notably, evidence for assessing COVID-19 mortality risk
has recently expanded beyond exploring diabetes status and
indicated that assessing blood glucose levels could further
identify at-risk individuals for adverse outcomes. Cariou and
colleagues report an age- and sex-independent association
between increased admission plasma glucose levels and the
severity of COVID-19, as well as early mortality at day 7,
among individuals with diabetes [1]. In our previous study
we also utilised admission glucose values to further categorise
patients into normo- and hyperglycaemic subgroups [8]. This
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glucose-based stratification allowed us to identify individuals at
further increased risk for CAPmortality. Compared with partic-
ipants with normal plasma glucose levels and without diabetes
at admission, the adjusted HR for death within 28 days after
admission in those with diabetes was 1.92 (95% CI 1.34, 2.75;
p < 0.001) and the observed mortality risk remained largely
unchanged for up to 180 days of follow-up [8].
Importantly, the clinical utility of glucose levels on admis-
sion appears to extend to CAP patients without pre-existing
diabetes. The study by Wang et al [2], as well as our previous
study [8], found a significant association between admission
glucose and CAP mortality outcome in individuals without
known diabetes. We reported that glucose levels on admission
in patients admitted for CAP but without pre-existing diabetes
(n = 5141) were significantly associated with all-cause mortal-
ity. In non-diabetic individuals 28- and 90-day mortality was
increased whether glucose concentrations were assessed by a
specific glucose threshold level (i.e. ≥6.0 mmol/l on admis-
sion; HR 1.71; 95% CI 1.22, 2.40; p for trend 0.001) or were
categorised in a stepwise manner (i.e. <4 mmol/l, 4–
5.99 mmol/l [reference group], 6–10.99 mmol/l [HR 2.89;
95% CI 2.27, 3.69], 11–13.99 mmol/l [HR 4.01; 95% CI
2.78, 5.81], and ≥14 mmol/l [HR 6.04; 95% CI 4.18, 8.74],
all p for trend <0.001). Interestingly, in our study, the almost
threefold mortality risk in individuals without diabetes but
with elevated glucose levels on admission within the moderate
range (6–10.99 mmol/l) was comparable to the HR for death
at 28 days seen for individuals with COVID-19 and an FBG
≥7.0 mmol/l as reported by Wang et al of 2.30 (95% CI 1.49,
3.55) [2].
Thus, the available evidence shows that mortality risk from
CAP (including COVID-19) is considerably increased in indi-
viduals with pre-existing diabetes, but also under conditions
of acutely elevated blood glucose levels, even in patients with-
out previously diagnosed diabetes. Based on these results,
clinical risk assessment based on pre-existing diabetes status
in individuals with COVID-19 is essential. If diabetes is pres-
ent, BMI, as well as rigorous and serial assessments of in-
hospital glucose levels (defined as at least one documented
2 h post-prandial glucose value exceeding 10 mmol/l) could
add further value for risk stratification [5]. However, it may be
difficult to obtain this information within a useful timeframe
for the latter, and we suggest that a single point-of-care
measurement of glucose, especially at standardised timepoints
(i.e. at hospital admission without a fasting period) could be an
attractive alternative. Notably, hospital admission glucose
may be of particular importance for people presenting with
COVID-19 without pre-existing diabetes, as this clinical
marker could identify at-risk individuals that may easily be
missed by solely assessing diabetes status.
In summary, evidence from large CAP cohorts (including
patients with and without COVID-19) from different
geographical regions and ethnic groups, strongly suggests that
individuals with pre-existing diabetes and/or elevated blood
glucose levels need special attention when presenting to a
hospital, as they represent a group at high risk for increased
mortality (Table 1). We believe admission glucose could
represent an attractive clinical tool for early and effective
CAP risk assessment as it is readily available in daily practice.
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Table 1 HRs for selected groups of patients with CAP, including COVID-19
Study Population Preexisting diabetes Patients (n) Glucose level (mmol/l) OR or HR (95% CI) for death p value
Cariou et al [1] COVID-19 Yes 1317 >5.55 Increased for death on day 7 0.0059
Zhu et al [5] COVID-19 Yes 952 Any HR 2.90 (2.21, 3.81) <0.001
Lepper et al [8] CAP Yes 1114 Any HR: 1.92 (1.34, 2.75) <0.001
No 5756 ≥6.0 HR: 1.69 (1.24, 2.30) <0.001
Wang et al [2] COVID-19 No 605 ≥7.0 HR: 2.30 (1.49, 3.55) 0.0002
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